Hong Kong Packaging Stock News

United Laboratories International Holdings Limited recently announced the successful completion of a Phase II clinical trial in China for its TUL01101 Tablets, a JAK1 inhibitor for treating moderate-to-severe atopic dermatitis in adults. The positive efficacy and safety results from this trial could open new opportunities for the company to expand into the competitive autoimmune disease treatment market. We will explore how advancing to Phase III trials positions United Laboratories to...

China Life Insurance Company Limited ( HKG:2628 ) shares have had a really impressive month, gaining 28% after a shaky...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Key Insights Easou Technology Holdings' significant retail investors ownership suggests that the key decisions are...

From what we can see, insiders were net buyers in Super Hi International Holding Ltd.'s ( HKG:9658 ) during the past 12...

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...

China Hongqiao Group Limited ( HKG:1378 ) shares have continued their recent momentum with a 29% gain in the last month...

1957 (Hospitality)'s (HKG:8495) stock is up by a considerable 80% over the past three months. Given that stock prices...

To the annoyance of some shareholders, Cinese International Group Holdings Limited ( HKG:1620 ) shares are down a...

Despite an already strong run, Solis Holdings Limited ( HKG:2227 ) shares have been powering on, with a gain of 29% in...

As global markets face a mix of challenges, including concerns over elevated valuations and geopolitical tensions, Asian markets have shown resilience with Chinese stocks gaining ground amid easing trade tensions. In this environment, identifying undervalued stocks can be particularly appealing to investors seeking opportunities to capitalize on potential market inefficiencies.

Key Insights AK Medical Holdings' significant insider ownership suggests inherent interests in company's expansion The...

The Impro Precision Industries Limited ( HKG:1286 ) share price has done very well over the last month, posting an...

As global markets grapple with fluctuating consumer sentiment and economic uncertainties, Asia's stock markets present a unique landscape where easing trade tensions and strategic pragmatism are fostering renewed investor interest. In this environment, identifying stocks that exhibit strong fundamentals and resilience can be particularly rewarding for investors seeking opportunities in the region's dynamic market landscape.

The Wai Chi Holdings Company Limited ( HKG:1305 ) share price has fared very poorly over the last month, falling by a...

Fosun International (SEHK:656) shares have seen some movement recently, sparking interest among those following the Hong Kong conglomerate. Investors are taking a closer look at how the group’s diversified operations might influence future performance. See our latest analysis for Fosun International. The share price of Fosun International has had its ups and downs lately, but the bigger story is its year-to-date share price return of 12.47%. This stands out against a longer five-year total...

MTR Corporation Limited has announced the appointment of Wilson Kwong Wing-tsuen as Hong Kong Transport Services Director and Executive Directorate Member, effective January 28, 2026, bringing extensive transportation and logistics industry experience to oversee key operational and commercial functions in Hong Kong. Kwong’s prominent roles in major organizations and receipt of a Medal of Honour highlight both his sector expertise and significant professional recognition, making this...

China Reinsurance (Group) (SEHK:1508) is updating its Articles of Association to align with recent regulatory changes, shifting oversight functions to the audit committee and removing its board of supervisors. The amendments await shareholder approval later this month. See our latest analysis for China Reinsurance (Group). China Reinsurance (Group)’s major overhaul of its corporate governance arrives at a time when momentum is gaining. After several executive and rulebook changes, the shares...

People's Insurance Company (Group) of China recently reported earnings results for the nine months ended September 30, 2025, with net income rising to CNY 46.82 billion from CNY 36.33 billion the prior year and basic earnings per share increasing from CNY 0.82 to CNY 1.06; shareholders also approved an interim dividend of RMB 0.75 per 10 Shares to be paid in December 2025. This combination of improved profitability and a higher interim dividend highlights management's confidence in the...

Innovent Biologics (SEHK:1801) is in focus after presenting early results from its first-in-human Phase 1 trial of IBI3016, a new RNA interference treatment for hypertension, at the American Heart Association scientific sessions. See our latest analysis for Innovent Biologics. Strong early data from Innovent’s novel RNAi hypertension treatment has certainly kept the spotlight on the stock, especially after a string of robust product launches and revenue growth. While the share price return...

China Zheshang Bank Co., Ltd recently announced its earnings for the nine months ended September 30, 2025, reporting net interest income of CNY 34,438 million and net income of CNY 11,668 million, both lower than the previous year’s figures. This decline in core profitability metrics highlights a challenging period for the bank, with earnings per share also slipping year over year. We’ll take a closer look at how the year-over-year drop in net income impacts China Zheshang Bank’s investment...

Lenovo PCCW Solutions (LPS) recently launched a Next-Gen IT Ecosystem, collaborating with 18 major technology partners to deliver integrated digital transformation services for enterprises across Hong Kong and Asia Pacific. This initiative brings together strengths in application software, cybersecurity, office automation, and infrastructure, positioning PCCW and its partners to support Hong Kong's ambitions as a leading innovation and technology hub. We'll examine how the partnership-driven...

Everest Medicines (SEHK:1952) has announced a new agreement with Visara Inc., gaining exclusive rights to develop and commercialize VIS-101 across Greater China and parts of Asia. This deal marks Everest's move into ophthalmology and broadens its late-stage product pipeline. See our latest analysis for Everest Medicines. Everest Medicines’ latest move into ophthalmology comes as the company’s momentum shifts, with the recent 1-year total shareholder return reaching an impressive 32.84%. The...

Yuexiu Property (SEHK:123) just released its October 2025 sales update, revealing an 8% decrease in contracted sales value and a 42% drop in gross floor area compared to the same period last year. See our latest analysis for Yuexiu Property. Yuexiu Property’s latest sales update arrives as the share price remains under pressure, closing at HK$4.70 after a year marked by persistent weakness. While recent news showed a modest pickup in year-to-date contracted sales value, overall momentum has...